It’s called…OA Fix.
The first ever global osteoarthritis clinical trial locator has been launched by a new nonprofit organization whose objectives are to significantly expand the number of patients with osteoarthritic (OA) joint pain’s knowledge and access to the full range of alternative treatments working their way through the regulatory process.
The group’s name, by the way, is Angry@Arthritis. The app they have developed is—OA Fix
“Today, more than 32 million American OA patients are blind to new OA treatments currently in development and approval,” said Angry@Arthritis Founder Steve O’Keeffe to OTW. “It’s you and the Google against the disease—and that’s simply not fair. Angry@Arthritis is the patient’s guide to OA; we’re focused on providing OA sufferers with direct access to the leading OA cure science through our podcast and this new OA Fix. The OA Fix provides the first patient guide to the innovative OA treatments that promise to regrow cartilage and save your joints—and the interactive chart allows you to locate and sign up for the most promising and relevant clinical trials.”
O’Keeffe commented, “As a patient with OA in multiple joints, I wanted to know more about the most viable developmental cures on the horizon, which treatments might work for the joints where I have the disease, and further, how I can sign up for clinical trials. I couldn’t find it—respectfully, clinicaltrials.gov is impossible to navigate—so, we decided to create that OA treasure map—the OA Fix.”
The Advanced Project Research Agency for Health recently announced its Novel Innovations for Tissue Regeneration in Osteoarthritis program to cure OA1. The funds are estimated to be over $1 billion dollars, with the goal of eliminating OA in 5 years.
“Today,” O’Keeffe told OTW, “there are promising new treatments that are repairing OA joints, such as the Swiss University of Basel N-TEC and American Cytex procedures. We are moving closer to OA cures. At the same time, the federal government’s Advanced Project Research Agency for Health announced the new Novel Innovations for Tissue Regeneration in Osteoarthritis program. Purportedly funded at $1 billion, the program aims to cure OA in five years—and make joint replacements a thing of the past. These are exciting times for OA.”
Jason Kim, Ph.D., vice president of OA research at the Arthritis Foundation, said, “The OA Fix chart is a great start to the fantastic new resource for the OA community. It provides a regularly updated and consolidated view of promising OA treatments—which would be an easy way for patients to gain visibility and access clinical trials as well.”
“Looking forward,” Steve O’Keeffe commented to OTW, “our goal for the next year is to make regular people more aware of the advances in OA treatments—there is light at the end of this tunnel. The University of Basel, N-TEC program just received $2.6 million in funding from the European Medical Agency—and is engaged in human clinical trials in knees, shoulders, ankles, and elbows. Cytex will go into human clinical trials for OA in hips this year.”
“We obviously hope to see great strides with the Novel Innovations for Tissue Regeneration in Osteoarthritis program—and want to make sure that all Americans are aware of, and cheering for, this OA cure moonshot program. We need to energize pharma, venture capital, and regular people to engage in funding innovative new OA cures. Go to www.angryatarthritis.org and get involved in finding a cure for OA.”
Reference
